Clinical Trial Update: A Study of the Safety and Pharmacokinetics of Escalating Doses of DCDT2980S in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia And DCDT2980S in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non Hodgkin's Lymphoma [Phase 1]

View source ↗

Summary

This Phase 1 trial evaluated escalating doses of DCDT2980S, both alone and in combination with rituximab, in adults with relapsed or refractory B-cell non-Hodgk…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Non-hodgkin Lymphoma

Drugs mentioned

• DCDT2980S
• Rituximab (rituximab)

Snippet

Sponsor: Genentech, Inc. | Conditions: Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 | Status: COMPLETED